 |
PDBsum entry 4akn
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Protein binding
|
PDB id
|
|
|
|
4akn
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
|
|
Key reference
|
|
|
Title
|
|
Identification of a novel series of bet family bromodomain inhibitors: binding mode and profile of i-Bet151 (gsk1210151a).
|
|
|
Authors
|
|
J.Seal,
Y.Lamotte,
F.Donche,
A.Bouillot,
O.Mirguet,
F.Gellibert,
E.Nicodeme,
G.Krysa,
J.Kirilovsky,
S.Beinke,
S.Mccleary,
I.Rioja,
P.Bamborough,
C.W.Chung,
L.Gordon,
T.Lewis,
A.L.Walker,
L.Cutler,
D.Lugo,
D.M.Wilson,
J.Witherington,
K.Lee,
R.K.Prinjha.
|
|
|
Ref.
|
|
Bioorg Med Chem Lett, 2012,
22,
2968-2972.
|
|
|
PubMed id
|
|
|
|
|
|
Abstract
|
|
|
A novel series of quinoline isoxazole BET family bromodomain inhibitors are
discussed. Crystallography is used to illustrate binding modes and rationalize
their SAR. One member, I-BET151 (GSK1210151A), shows good oral bioavailability
in both the rat and minipig as well as demonstrating efficient suppression of
bacterial induced inflammation and sepsis in a murine in vivo endotoxaemia model.
|
|
|
|
|
|
|
